Oruka Therapeutics (ORKA) is in focus after Russell index rebalancing on 27 June 2026 shifted the stock out of several value benchmarks and into multiple growth benchmarks, prompting potential passive fund repositioning.

Beyond the index reshuffle, Oruka Therapeutics has seen a 40.51% 1 month share price return and a 36.27% 3 month share price return, contributing to a 198.90% year to date share price return and a very large 1 year total shareholder return. This suggests momentum has been building ahead of and around the Russell rebalancing.

If recent moves in Oruka Therapeutics have sparked your interest in growth stories, this could be a good moment to widen your search with the 40 healthcare AI stocks

After a move that has already driven Oruka Therapeutics sharply higher and shifted it into growth indexes, the next step is to test whether current pricing still leaves meaningful upside on the table or has already captured most of the story.

Preferred Price-to-Book Multiple of 10.5x: Is it justified?

With Oruka Therapeutics closing at $84.50 and carrying a P/B ratio of 10.5x, the stock trades well above the broader US Biotechs industry on this yardstick, even though, relative to a selected peer group, it screens as cheaper.

The price to book ratio compares a company’s market value to its book value, which is effectively the accounting value of its net assets. For early stage biopharmaceutical companies like Oruka Therapeutics that are currently loss making and have limited revenue, P/B is often used because traditional earnings based multiples such as P/E are not meaningful.

According to the data, Oruka Therapeutics is described as good value on a P/B basis versus peers, with its 10.5x multiple sitting below a peer average of 43.1x. At the same time, that same 10.5x multiple is characterised as expensive versus the wider US Biotechs industry, where the average is 2.8x, indicating investors are assigning a much richer valuation than the sector norm.

That contrast highlights how Oruka Therapeutics sits in a higher expectation bracket than the overall industry while still pricing in less optimism than its closest valuation peers.

Result: Price-to-book of 10.5x (ABOUT RIGHT)

However, Oruka Therapeutics still faces key risks, including ongoing clinical trial uncertainty and a reported loss of $94.19 million, which could pressure future funding options.

Next Steps

If the strong recent momentum in Oruka Therapeutics leaves you unsure how to balance upside potential against clinical and funding risks, act quickly and review the underlying data so you can form your own judgment, starting with the 4 important warning signs.

Looking for more investment ideas beyond Oruka Therapeutics?

If Oruka Therapeutics has sharpened your focus, do not stop here. Broaden your watchlist with other stocks that match clear, data driven criteria.

• Spot potential turnaround opportunities early by scanning 20 elite penny stocks with strong financials that already meet strict financial quality filters.
• Zero in on companies where quality and valuation line up using the 45 high quality undervalued stocks to see which stocks screen as attractively priced.
• Strengthen the core of your portfolio by reviewing the solid balance sheet and fundamentals stocks screener (47 results) and focusing on businesses with healthier financial foundations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.